Overall, for gastrointestinal tumors closely linked to homologous recombination deficiency, especially pancreatic cancer, attention should be given to the use of PARP inhibitors and platinum-based chemotherapy regimens. Here, PARP1 is linked to familial pancreatic carcinoma.